Prognosis
Eli Lilly Antibody Cuts Covid-19 Risk Up to 80% in Nursing Home Study
- Drugmaker studies antibody therapy as preventive treatment
- Infusion reduced risk of Covid-19 symptoms by as much as 80%
This article is for subscribers only.
Eli Lilly & Co.’s antibody therapy reduced nursing home residents’ risk of symptomatic Covid-19 by as much as 80% when used preventively in a study.
The infused treatment, cleared for use in high-risk Covid patients with mild-to-moderate disease who haven’t been hospitalized, also significantly reduced the risk of symptomatic disease in nursing home workers, according to a statement from Lilly on Thursday.